Keywords: study, shows, patients, prefer, granisetron, 5-ht3, antiemetic
STUDY SHOWS PATIENTS PREFER GRANISETRON
Article | 22 November 1993
The 5-HT3 antiemetic granisetron (SmithKline Beecham's Kytril) may be "preferred" by a higher proportion of patients than its competitors ondansetron ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
